Simultaneous Estimation of Ombitasvir, Paritaprevir and Ritonavir in Tablet Dosage Form by Reverse Phase High-Performance Liquid Chromatography
Pharmaceutical Science-Pharmaceutical Analysis
DOI:
https://doi.org/10.22376/ijpbs/lpr.2022.12.4.P107-114Keywords:
Hepatitis C virus, Dosage forms, RP- HPLC, Validation, Quality controlAbstract
Ombitasvir/paritaprevir/ritonavir are the newest medicines approved for use in the treatment of hepatitis C virus (HCV) and are available in tablet form as an oral combination. Specifically, these agents are indicated in the treatment of HCV in patients with genotype 1 infection. Due to the therapeutic importance and increased use of Viekira Pak, proper methods for its determination in bulk and pharmaceutical formulations must be developed. The purpose of this work is to develop an accurate and precise RP-HPLC method for the determination of ombitasvir, paritaprevir and ritonavir in bulk and pharmaceutical preparations. Drugs were separated using Inertsil ODS-C18; 5μm (4.6 X 250mm) column using a mobile phase consisting of 0.02M phosphate buffer (pH-4.5): Acetonitrile: Methanol, (50:30:20) (v/v). The retention time was 2.98, 3.77 and 4.70 min for Ombitasvir, Paritaprevir, Ritonavirrespectively and total run time was 10 min. at a flow rate of 1.0 mL/ min and the detection wavelength was 262 nm. The linearity was observed in the range of 15-45μg/ mL for ombitasvir, paritaprevir and ritonavir with a correlation coefficient of 0.9903, 0.9996 and 0.9998 respectively. The proposed method was validated for its linearity, accuracy, precision and robustness. This method can be employed for routine quality control analysis of Ombitasvir, Paritaprevir and Ritonavir in tablets. The LOD and LOQ values were found to be 1.8, 0.29 and 0.69 μg/ mL and 5.7, 0.90 and 2.10 μg/ mL for Ombitasvir, Paritaprevir and Ritonavir, respectively. The proposed method was successfully applied for the determination of ombitasvir/paritaprevir/ritonavir tablets, without interference from the excipient peaks. Hence, the method can be applied for the routine quality control analysis of the studied drugs, either in bulk or dosed forms.
References
Hong H., Thakkar S., Chen M., Tong W. Development of decision forest models for prediction of drug-induced liver injury in humans using a large set of FDA-approved drugs. Sci. Rep. 2017; 7:17311.
Talal A.H., Dumas E.O., Bauer B., Rejman R.M., Ocque A., Morse G.D., Lucic D., Cloherty G.A., King J., Zha J. Hepatic pharmacokinetics and pharmacodynamics with ombitasvir/paritaprevir/ritonavir plus dasabuvir treatment and variable ribavirin dosage. J. Infect. Dis. 2017;217:474–482.
Medisetti Pravallika, Dr. Devanaboyina Narendra and Gadi Vijaya Lakshmi. Method development and validation for simultaneous estimation of ritonavir, ombitasvir & paritaprevir by RP-HPLC method. ejpmr, 2020,7(7), 849-855.
Maneka, S. L., R. T. Saravanakumar, and A. Male. “Stability-Indicating Method Development and Validation for Simultaneous Estimation of Ombitasvir, Paritaprevir, and Ritonavir in Formulation by Ultra Performance Liquid Chromatography”. International Journal of Pharmaceutical Sciences and Drug Research, Vol. 12, no. 5, Sept. 2020, pp. 457-63.
Baje, S. I., Jyothi, B., & Madhavi, N. (2019). RP-HPLC Method for Simultaneous Estimation Of Ritonavir, Ombitasvir And Paritaprevir In Tablet Dosage Forms And Their Stress Degradation Studies. International Journal of Applied Pharmaceutics, 11(2), 193-210.
Kuna M., Dannana G.S. Stability-indicating RP-HPLC method for simultaneous quantification of ombitasvir, paritaprevir and ritonavir in tablet dosage form. Asian J. Chem. 2018;30.
Saraya R.E., Elhenawee M., Saleh H. Development of a highly sensitive high-performance thin-layer chromatography method for the screening and simultaneous determination of sofosbuvir, daclatasvir, and ledipasvir in their pure forms and their different pharmaceutical formulations. J. Sep. Sci. 2018;41:3553–3560.
Wadie MA, Mostafa SM, El SM, Elgawish MS. Development and validation of a new, simple-HPLC method for simultaneous determination of ombitasvir, paritaprevir, ritonavir and ribavirin in tablet dosage form. Iosr journal of pharmacy and biological sciences. 2017;12(6): 28-35.
Jahnavi B, Ganapaty S. Stability indicating RP-HPLC method development and validation for the simultaneous determination of ombitasvir, paritaprevir, and ritonavir in tablet dosage forms. Asian Journal of Pharmaceutical Education and Research. 2018;7(1):90-101.
Ibrahim A.E., Hashem H., Saleh H., Elhenawee M. Performance comparison between monolithic, core-shell, and totally porous particulate columns for application in greener and faster chromatography. J. AOAC Int. 2018; 101:1985–1992.
Ibrahim A.E., Hashem H., Elhenawee M., Saleh H. Comparison between core–shell and totally porous particle stationary phases for fast and green LC determination of five hepatitis-C antiviral drugs. J. Sep. Sci. 2018;41:1734–1742.
Al-Zoman NZ, Maher HM, Al-Subaie A. Simultaneous determination of newly developed antiviral agents in pharmaceutical formulations by HPLC-DAD. Chemistry Central Journal. 2017;11(1): 2-8.
Ocque AJ, E Hagler CE, Difrancesco R, Woolwine-Cunningham Y, Bednasz CJ, Morse GD, Talal AH. Development and validation of a UPLC-MS/MS method for the simultaneous determination of paritaprevir and ritonavir in rat liver. Bioanalysis. 2016;8(13):1353-1363S.
Sadanshio PP, Wankhede SB, Chaudhari PD. A validated stability indicating HPTLC method for estimation of ribavirin in capsule in presence of its alkaline hydrolysis degradation product. Anal Chem Lett. 2015;4:343–358.
Shi X, Zhu D, Lou J, Zhu B, Hu AR, Gan D. Evaluation of a rapid method for the simultaneous quantification of ribavirin, sofosbuvir and its metabolite in rat plasma by UPLC–MS/MS J Chromatogr B Anal Technol Biomed Life Sci. 2015;1002:353–357.
Rezk MR, Basalious EB, Karim IA. Development of a sensitive UPLC-ESI-MS/MS method for quantification of sofosbuvir and its metabolite, GS-331007, in human plasma: application to a bioequivalence study. J Pharm Biomed Anal. 2015;114:97–104.
Rezk MR, Basalious EB, Karim IA. Development of a sensitive UPLC-ESI-MS/MS method for quantification of sofosbuvir and its metabolite, GS-331007, in human plasma: application to a bioequivalence study. J Pharm Biomed Anal. 2015;114:97–104.
Killi GD, Maddinapudi RK, Dinakaran SK. A novel validated UPLC method for quantitation of lopinavir and ritonavir in bulk drug and pharmaceutical formulation with its impurities. Braz J Pharm Sci. 2014;50:301–308.
Kumar KV, Sudhakar M, Reddy YP, Malleshwari P, Hafeez SK. RP-HPLC method development and validation for simultaneous estimation of lopinavir and ritonavir in dosage form and in plasma. Int J Pharm Res Rev. 2014;3:1–8.
Aouri M, Moradpour D, Cavassini M, Mercier T, Buclin T, Csajka C, Telenti A, Rauch A, Decosterd TA. Multiplex liquid chromatography-tandem mass spectrometry assay for simultaneous therapeutic drug monitoring of ribavirin, boceprevir, and telaprevir. Antimicrob Agents Chemother. 2013;57:3147–3158.
Pabolu HK, Konidala SK. New validated RP-HPLC method for the determination of ritonavir in bulk and pharmaceutical dosage form. Int J Pharm Pharm Sci. 2013;5:556–559.
Abdelhay MH, Gazy AA, Shaalan RA, Ashour HK. Validated stability-indicating HPLC and HPTLC methods for the determination of ritonavir in bulk powder and in capsules. J Food Drug Anal. 2012;20:963–973.
Jagadeeswaran M, Gopal N, Kumar KP, Kumar TS. Quantitative estimation of lopinavir and ritonavir in tablets by RP-HPLC method. Pharm Anal Acta. 2012;3:3–5.
Hendrikx JJ, Hillebrand MJ, Thijssen B, Rosing H, Schinkel AH, Schellens JH, Beijnen JH. A sensitive combined assay for the quantification of paclitaxel, docetaxel and ritonavir in human plasma using liquid chromatography coupled with tandem mass spectrometry. J Chromatogr B Anal Technol Biomed Life Sci. 2011;879:2984–2990.
Sun H, Wang H, Ge X, Qin X. Simultaneous determination of the combined drugs ribavirin and ceftriaxone sodium in human urine by HPLC-DAD. Int J Sci Innov Dis. 2011;1:216–225.
Breadmore MC, Theurillat R, Thormann W. Determination of ribavirin in human serum and plasma by capillary electrophoresis. Electrophoresis. 2004;25:1615–1622.
Gutleben W, Tuan ND, Stoiber H, Dierich MP, Sarcletti M, Zemann A. Capillary electrophoretic separation of protease inhibitors used in human immunodeficiency virus therapy. J Chromatogr A. 2001;922:313–320.
ICH: Q2(R1), validation of analytical procedures: text and methodology;2005.
ICH: Q2B. Harmonized Tripartite Guideline, Validation of Analytical Procedure: Methodology, IFPMA, in: Proceedings of the International Conference on Harmonization, Geneva;1996.
ICH Guidelines Q1A (R2), Stability Testing of New Drug Substances and Products, International Conference on Harmonization;2003.
Published
How to Cite
Issue
Section
Copyright (c) 2022 Gollapalli Nagaraju, Ritesh Agarwal, Rama Rao Nadendla
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
